Navigation Links
Merck Announces Plans for Licensing Atripla Widely in Developing World

Merck & Co is seeking to register its three-in-one fixed dose combination Atripla in 66 developing countries, in addition to seeking// World Health Organization prequalification for the product, the company announced on Friday.

Atripla, which is a single tablet containing a daily dose of efavirenz, tenofovir and emtricitabine, will be priced at $613 a year for least developed countries and higher prevalence middle income countries (>1% HIV prevalence), and $1032 a year for other middle-income countries that qualify for a discounted price.

Atripla will be sold in developing countries as a white tablet in order to differentiate it from the salmon-pink tablet sold in the United States, in order to reduce the risk of diversion of product from developing countries.

Atripla is a collaboration between Merck, the license holder for efavirenz outside the US and western Europe, and Gilead, the license holder of tenofovir and emtricitabine. In contrast to Gilead's policy with tenofovir, where the company has granted voluntary licenses in India and South Africa, Atripla commercialisation will remain in the hands of the patent holders. This is likely to prevent any significant competitive pressure on the price of the product, since once licenses are granted, competition from generic versions of this fixed dose combination will be impossible without the granting of compulsory licenses for rival versions.

Although Merck will be able to import Atripla into eleven countries on the basis of US Food and Drug Administration registration, licensing in other countries may take several years in some cases owing to lack of regulatory agency capacity. Tenofovir, one of the components of Atripla, remains unlicensed in South Africa despite the grant of a voluntary license for the product to South African manufacturer Aspen in 2004. According to the Treatment Action Campaign, Aspen’s version of tenofovir was already under fast track review by South Africa’s Medicines Control Council in June 2006.

The combination of efavirenz, tenofovir and emtricitabine has been recommended by the World Health Organization as a preferred first-line combination wherever it is available, because of the reduced risk of toxicity when compared to a stavudine (d4T)-based regimen.

Source-Bio-Bio Technology
SR
'"/>




Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck in the Dock Due To Vioxx
7. Merck Says Januvia Effective In Type 2 Diabetes
8. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
9. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
10. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
11. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: